Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trinity Biotech (TRIBY) -- Ignore unavailable to you. Want to Upgrade?

To: Ace who wrote (9120)	5/5/1998 8:20:00 PM
From: Ace	Read Replies (2) \| Respond to of 14328

Everyone thought the press release today would be the catalyst to move Triby above 3 on qrt .02 earnings... Technicaly speaking, chart says trading range from 1.75 to 2.50 with support at 2.10 and resistance around 2.30. About new shares : 2,251,000 of insider shares are locked up for five years and out of 1,427,142 in the Clark Labs aquis. two thirds are locked up for 1 to 2 yrs. so all the new shares are not being actively traded. Cancer research has become a hot topic and with Triby holding 7% in CLI's technology and the addition of Centocor's tumor markers we are sitting on a gold mine... Trinity will develop both rapid and laboratory EIA tests including CA15-3“ (breast cancer), CA125“ (ovarian cancer), CA19-9“ (pancreatic cancer), CA72-4“ (gastrointestinal cancer) and free and total prostate specific antigen (PSA). These products are in vitro diagnostic blood tests used by physicians to monitor the growth or disappearance of tumours before and after treatment and are selectively used by physicians to diagnose and monitor the development of cancers in patients. We should not forget about Tribys plan to be listed on the Irish Exchange...Big + OTC ? Been on the job one day and getting the thumbs down. Give them a chance, maybe they have turned over a new leaf .